Anixa Biosciences, Inc.
Anixa Biosciences, Inc.（ANIX）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · ANIX · 截至 2026年6月9日
活动摘要
买入笔数
7
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
Anixa Biosciences, Inc.内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
ANIX 季度内部人买卖趋势
ANIX 内幕交易卖出 · ANIX 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · ANIX CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
ANIX 高管卖出股份 · ANIX 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jan 28, 2026 | Baskies Arnold M Director | Purchase | 10,000 | $30K | Form 4 |
| Dec 15, 2025 | Titterton Lewis H jr Director | Option | 16,000 | $47K | Form 4 |
| Oct 30, 2025 | KUMAR AMIT CEO | Option | 200,000 | $584K | Form 4 |
| Oct 30, 2025 | KUMAR AMIT CEO | Other | 169,439 | $688K | Form 4 |
| Jul 31, 2025 | Titterton Lewis H jr Director | Purchase | 10,000 | $31K | Form 4 |
| Jul 30, 2025 | KUMAR AMIT CEO | Purchase | 5,000 | $16K | Form 4 |
| Jul 18, 2025 | Baskies Arnold M Director | Purchase | 5,000 | $17K | Form 4 |
| Jul 11, 2025 | Titterton Lewis H jr Director | Purchase | 10,000 | $31K | Form 4 |
| Jul 11, 2025 | KUMAR AMIT CEO | Purchase | 5,000 | $16K | Form 4 |
| Jun 4, 2025 | KUMAR AMIT CEO | Purchase | 10,000 | $29K | Form 4 |
| Jan 28, 2025 | Baskies Arnold M Director | Purchase | 5,000 | $14K | Form 4 |
| Jan 24, 2025 | Titterton Lewis H jr Director | Purchase | 1,000 | $3K | Form 4 |
| Jan 23, 2025 | Titterton Lewis H jr Director | Purchase | 2,000 | $6K | Form 4 |
| Jan 22, 2025 | Titterton Lewis H jr Director | Purchase | 2,000 | $6K | Form 4 |
| Jan 21, 2025 | Titterton Lewis H jr Director | Purchase | 6,000 | $16K | Form 4 |
| Jan 17, 2025 | Titterton Lewis H jr Director | Purchase | 10,000 | $26K | Form 4 |
| Jan 15, 2025 | KUMAR AMIT CEO | Purchase | 43,000 | $96K | Form 4 |
| Jan 15, 2025 | Catelani Michael President, COO, & CFO | Purchase | 9,289 | $20K | Form 4 |
| Oct 22, 2024 | Titterton Lewis H jr Director | Option | 16,000 | $41K | Form 4 |
| Jul 31, 2024 | Titterton Lewis H jr Director | Purchase | 5,580 | $18K | Form 4 |
| Jul 30, 2024 | Titterton Lewis H jr Director | Purchase | 21,646 | $66K | Form 4 |
| Jul 26, 2024 | Titterton Lewis H jr Director | Purchase | 7,700 | $23K | Form 4 |
| Jul 25, 2024 | Titterton Lewis H jr Director | Purchase | 796 | $2K | Form 4 |
| Jul 26, 2024 | Baskies Arnold M Director | Purchase | 5,000 | $15K | Form 4 |
| Jun 14, 2024 | Titterton Lewis H jr Director | Purchase | 4,000 | $11K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ANIX 内幕交易
ANIX 内幕交易
Anixa Biosciences, Inc.（ANIX）内幕交易数据来源于公司内部人（包括KUMAR AMIT (CEO), Titterton Lewis H jr (Director), Baskies Arnold M (Director)）提交的SEC Form 4申报文件。过去12个月内，3位内部人向SEC提交了交易申报。ANIX内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Anixa Biosciences, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
ANIX 内幕交易 · 5个问题Anixa Biosciences, Inc.（ANIX）的内部人包括高管和董事，如KUMAR AMIT (CEO), Titterton Lewis H jr (Director), Baskies Arnold M (Director)等。过去12个月内，3位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026